Amyloidosis represents a group of human diseases in which protein precursors exhibit altered secondary structure and form insoluble protein aggregates in tissues. Primary amyloidosis (AL) is the most common systemic amyloidosis and is initiated by the clonal production of immunoglobulin light chain (LC) proteins by plasma cells. While AL aggregates may form in numerous organs, cardiac deposition is associated with the worst prognosis. The resulting amyloid AL cardiomyopathy is unique in that it is not responsive to standard heart failure regimens and is accompanied by greater than 50% mortality over 5 years, comparable to the most aggressive types of cancers. To date, there is no treatment for AL cardiomyopathy, other than orthotopic transplantation, owing to the lack of understanding of the molecular mechanisms that underlie this disease process. During the past funding cycle, our laboratory has provided the first mechanistic insight into the pathogenesis of AL cardiomyopathy and demonstrated that human amyloidogenic LC (AL-LC) provoke a cardiotoxic effects via activation of non-canonical p38 MAPK signaling cascade and subsequently lead to increase cellular oxidant stress, altered calcium homeostasis, impaired cellular contractility, and, eventually, cell death. Through the use of unbiased genomics we have recently identified a novel cardiomyocyte regulator of LC toxicity, stanniocalcin-1 (STC1), from whole genome transcriptomic analyses of AL-LC treated cardiomyocytes and explanted human hearts with AL cardiomyopathy. Moreover, we find that upregulation of STC1 is dependent upon upstream p38 MAPK activation, and that STC1 localizes to the cardiomyocyte mitochondria, where it induces ROS generation, cellular dysfunction and death in isolated adult cardiomyocytes via the inhibition of autophagy clearance. With our prior findings and preliminary data, in this competitive renewal application, we propose to test our central hypothesis that that circulating AL-LC imparts a deleterious effect on cardiomyocytes via STC1 impairment of mitochondrial function and dysregulation of cellular autophagy. Utilizing a multidisciplinary approach of molecular and cellular biology, biochemistry, and physiology, coupled with isolated cardiomyocyte and in vivo mouse models, we will determine the necessity and sufficiency of STC1 (Aim 1) and the role of autophagy (Aim 2) in AL-LC induced deleterious events. This work represents our continued intensive investigation of the mechanism underlying amyloid cardiomyopathy.

Public Health Relevance

Primary amyloidosis (AL) is the most common systemic amyloidosis and frequently results in the development of amyloid heart disease. There is no cure for this form of heart disease, and it is associated with greater than 50% mortality over 5 years, comparable to the most aggressive types of cancers. This grant proposal aims to understand the molecular mechanisms that drive the development of amyloid heart disease, and in doing so, identify novel therapeutic targets.

National Institute of Health (NIH)
National Heart, Lung, and Blood Institute (NHLBI)
Research Project (R01)
Project #
Application #
Study Section
Cardiac Contractility, Hypertrophy, and Failure Study Section (CCHF)
Program Officer
Wang, Lan-Hsiang
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Brigham and Women's Hospital
United States
Zip Code
Liao, Ronglih; Ward, Jennifer E (2017) Amyloid Cardiomyopathy: Disease on the Rise. Circ Res 120:1865-1867
Sapp, Valerie; Jain, Mohit; Liao, Ronglih (2016) Viewing Extrinsic Proteotoxic Stress Through the Lens of Amyloid Cardiomyopathy. Physiology (Bethesda) 31:294-9
Kuster, Gabriela M; Liao, Ronglih (2016) Fortune Favors the Prepared: Safety and Efficacy of Allogeneic Hypoxia Preconditioned Mesenchymal Stromal Cells in Primates. Circ Res 118:908-10
Cheng, Hui-Wen; Fisch, Sudeshna; Cheng, Susan et al. (2014) Assessment of right ventricular structure and function in mouse model of pulmonary artery constriction by transthoracic echocardiography. J Vis Exp :e51041
Hiremath, Pranoti; Bauer, Michael; Aguirre, Aaron D et al. (2014) Identifying early changes in myocardial microstructure in hypertensive heart disease. PLoS One 9:e97424
Guan, Jian; Mishra, Shikha; Qiu, Yiling et al. (2014) Lysosomal dysfunction and impaired autophagy underlie the pathogenesis of amyloidogenic light chain-mediated cardiotoxicity. EMBO Mol Med 6:1493-507
Hiremath, Pranoti; Bauer, Michael; Cheng, Hui-Wen et al. (2014) Ultrasonic assessment of myocardial microstructure. J Vis Exp :e50850
Liao, Ronglih (2014) Worming along in amyloid cardiotoxicity. Blood 123:3525-6
Guan, Jian; Mishra, Shikha; Shi, Jianru et al. (2013) Stanniocalcin1 is a key mediator of amyloidogenic light chain induced cardiotoxicity. Basic Res Cardiol 108:378
Bauer, Michael; Cheng, Susan; Unno, Kazumasa et al. (2013) Regional cardiac dysfunction and dyssynchrony in a murine model of afterload stress. PLoS One 8:e59915

Showing the most recent 10 out of 24 publications